FibroGenesis Files Patent Using its Fibroblast Cell Therapy for Coronavirus (COVID-19) ARDS
PR83238
HOUSTON, March 10, 2020 /PRNewswire=KYODO JBN/ --
FibroGenesis(https://c212.net/c/link/?t=0&l=en&o=2745542-1&h=2022740774&u=http%3A%2F%2Fwww.fibro-genesis.com%2F&a=FibroGenesis ),
a Texas-based regenerative medicine company focused on tissue regeneration and
chronic disease reversal using Human Dermal Fibroblasts (HDFs), today announced
the filing of United States Provisional Patent Number 62/986,339 titled, "Fibroblast and
TLR Activated Fibroblast Treatment of Viral Induced Acute Respiratory Distress Syndrome."
Logo - https://mma.prnewswire.com/media/1121989/FibroGenesis_Logo.jpg
The claims in the patent include utilization of universal donor cell therapies
for treatment of Acute Respiratory Distress Syndrome (ARDS), which is one of
the major causes of Coronavirus associated deaths. The disclosure addresses
the unmet need by providing a novel therapeutic agent in the treatment of ARDS
using fibroblasts as toll-like receptors which activates fibroblasts as a means
of dampening ARDS, while producing factors such as inteferons to stimulate
anti-viral immunity.
"We have known about the regenerative and anti-inflammatory properties of
fibroblasts, but our research continues to discover many other benefits of this
'super-cell,'" commented Tom Ichim, Ph.D., Chief Scientific Officer of
FibroGenesis. "COVID-19 mortality centers around ARDS and we are finding
compelling data to potentially cure this deadly condition with fibroblasts.
We have demonstrated that our cells are capable of producing interferon.
Hypothetically, this endows our cells not only with the ability to suppress
ARDS, but also allows the cells to possess a direct anti-viral effect."
"As we continue to expand our clinical knowledge of fibroblasts, we are finding
their therapeutic benefit across a broad chronic disease platform," said Pete
O'Heeron, Chief Executive Officer, FibroGenesis. "Discovering fibroblasts can
potentially cure the leading cause of death from COVID-19, encouraging us to
expedite the clinical testing needed to validate their benefit."
About COVID-19 Induced ARDS
Acute respiratory distress syndrome (ARDS) is a type of severe acute lung
dysfunction affecting all or most of both lungs and can be a severe
complication of viral infections including COVID-19. When afflicting older
patients with co-morbidities such as diabetes, asthma or heart disease, it can
result in a high death rate.
ARDS is a serious condition with associated high mortality that afflicts
approximately 200,000 people in the United States each year, leading to
approximately 75,000 deaths. A number of clinical trials of treatments for ARDS
have been conducted and to date none have been proved highly effective;
therefore, there is a great need for new, more effective treatments.
It is known that ARDS is often associated with fluid accumulation in the lungs.
When this occurs, the elastic air sacs (alveoli) in the lungs fill with fluid
and the function of the alveoli is impaired. The result is that less oxygen
reaches the bloodstream, depriving organs of the oxygen required for normal
function and viability. Severe shortness of breath, the main symptom of ARDS,
usually develops within a few hours to a few days after the precipitating
injury or infection.
There are currently no effective pharmacologic therapies for treatment or
prevention of ARDS. While inhibition of fibrin formation mitigated injury in
some preclinical models of ARDS, anticoagulation therapies in humans do not
attenuate ARDS and may even increase mortality. Protective lung ventilator
strategies remain the mainstay of available treatment options. Due to the
significant morbidity and mortality associated with ARDS and the lack of
effective treatment options, new therapeutic agents for the treatment of ARDS
and new treatment methods for ARDS are needed.
About FibroGenesis
Based in Houston, Texas, FibroGenesis, is a regenerative medicine company
developing an innovative solution for chronic disease treatment using human
dermal fibroblasts. Currently, FibroGenesis holds 184 U.S. and international
issued patents/patents pending across a variety of clinical pathways, including
Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic
Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded
entirely by angel investors, FibroGenesis represents the next generation of
medical advancement in cell therapy.
Visit www.Fibro-Genesis.com.
SOURCE: FibroGenesis
CONTACT: Clinical Contact: info@Fibro-Genesis.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。